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People & Ideas
C
ells keep a record of their devel-
opmental history by chemically 
modifying their histones and 
DNA to alter chromatin structure and 
control gene expression. Resetting these 
epigenetic marks is an essential step in 
reprogramming adult cells to produce 
embryonic stem (ES)–like cells able to 
develop into every tissue of the body.
Alex Meissner fi   rst became inter-
ested in epigenetics as a graduate student 
with Rudolf Jaenisch at the Whitehead 
Institute in Cambridge, MA, where he 
studied cellular reprogramming through 
nuclear transfer. To mitigate ethical con-
cerns over the destruction of viable blas-
tocysts, he devised an alternate nuclear 
transfer method that used blastocysts 
incapable of implantation and in utero 
development (1). When Shinya Yamanaka’s 
group discovered that just four transcrip-
tion factors were suffi   cient to convert 
somatic cells into induced pluripotent 
stem (iPS) cells, Meissner’s work in the 
Jaenisch laboratory put him in a good 
position to improve the new technique 
(2, 3). Having adapted bisulfi  te sequenc-
ing methods to identify DNA methylation 
sites  across the entire 
genome (4, 5) Meiss-
ner  dissected some of 
the steps involved in 
reprogramming by mea-
suring the epigenetic 
changes induced during 
the process (6). Increas-
ing the effi  ciency  and 
safety of iPS cell pro-
duction is vital if these 
cells are to fulfi  ll their 
therapeutic potential in 
regenerative medicine, but Meissner is 
also interested in epigenetic changes asso-
ciated with normal development and dis-
eases such as cancer.
In 2008, Meissner became a group 
leader at both Harvard University and 
the Broad Institute. In a recent inter-
view, Meissner discussed the events that 
marked the development of his own career 
to date.
ENGINEERING BACKGROUND
How did you get interested in science?
I grew up in Germany and after high 
school I joined a biotechnology program 
at the Technical University in Berlin that 
was focused on engineering rather than 
basic science. I only had one genetics and 
maybe one biochemistry course, so I never 
really thought about biology research. But 
I did a lot of internships with some small 
biotech companies and started learning a 
little bit more biology.
The big change came when I got 
an internship at the Dana-Farber Cancer 
Institute, where I started doing “proper” 
biology. During that time, I learned about 
Rudolf Jaenisch’s work on nuclear trans-
fer, which sounded much more interesting 
than the engineering training I’d had. I 
contacted him to see whether I could learn 
about nuclear transfer. That led to me join-
ing his laboratory and not leaving for an-
other eight years!
How did your ﬁ  rst project in the 
Jaenisch laboratory come about?
During my fi  rst year, I spent a lot of time 
learning about nuclear transfer, so when we 
came up with an idea for 
alternate nuclear transfer, 
I was one of the few peo-
ple who could actually do 
all of the experiments.
It was mostly to 
show, as a proof of 
principle, that there are 
alternative ways to cre-
ate pluripotent cells 
that don’t involve us-
ing blastocysts capable 
of implantation. That’s 
where my engineering background came 
in: I thought, well, if there’s a problem, 
you can engineer a solution. In this case, 
we blocked the cdx2 gene so that the blas-
tocysts could never implant. That went 
well, although it’s still a controversial 
approach, but we never meant to claim that 
it was the best way to do it. We just wanted 
to stimulate a discussion and get people to 
think about other possible solutions.
THE MAGIC TRANSFORMATION
Then Yamanaka published the ﬁ  rst iPS 
cell paper. Did that come completely out 
of the blue?
There was an idea that something like that 
might work, because the nuclear transfer 
experiments and a few studies using cell 
fusion showed that you can reprogram a so-
matic cell. And whatever factors are present 
in oocytes are also present in ES cells, be-
cause if you fuse an ES cell to a somatic cell, 
it will also reprogram. So there must be a 
defi  ned set of factors present, and by looking 
at these different cell types, you could already 
guess which factors might be involved.
In fact, I—along with several postdocs 
in the Jaenisch laboratory—had already 
made inducible vectors for Oct4 and had 
also guessed Sox2, but those two alone 
weren’t suffi  cient to reprogram anything. 
So although the Yamanaka group’s discov-
ery of c-Myc and Klf4 was a surprise, the 
notion that you could put in a defi  ned set of 
factors to reprogram cells was expected.
That being said, when Yamanaka fi  rst 
presented his result at a Keystone meeting 
in Whistler, there was a lot of skepticism in 
the audience. But Yamanaka was right and 
there were three papers shortly afterwards, 
including one from us in the Jaenisch group, 
that repeated the experiment and proved it. 
That happened so fast because half of the 
system was already present.
It’s amazing though: it’s one of the 
most robust things that I’ve seen in my ca-
reer. People might fail to repeat a published 
PCR protocol, but this magic transforma-
tion seems to be easy; everybody can do it.
Meissner studies the epigenomics of pluripotent cells.
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Is there no longer interest in nuclear 
transfer?
There’s minor interest; it’s still a remark-
able process. If you put a somatic nucleus 
into an oocyte, you can reprogram it with-
in a day or two; it happens with very few 
cell divisions. With iPS cells, reprogram-
ming takes one to three weeks, and cells 
divide quite a few times. It’s not clear why 
this is so slow, so I think there might still 
be some use for nuclear transfer in studying 
the basic mechanism involved.
But there’s certainly no therapeutic 
application for it in regenerative medi-
cine. It involves the donation of oocytes, 
it’s technically very challenging, and there 
doesn’t seem to be a way of mass producing 
customized stem cells.
What is it like to work in a ﬁ  eld that 
generates such public interest?
It’s very interesting, but also complicated. 
It’s one of the few things that actually makes 
it onto the front pages once in a while. That’s 
a good thing, and most people can easily 
understand what a stem cell is, and why its 
potential is so interesting. So you can talk to 
them about it, which is fun, because if you 
work on a complicated protein network, or 
something like that, it’s hard to explain to 
your friends or family what you’re actually 
doing. Even if other scientists talk to me 
about a complex problem in their specifi  c 
fi  eld, I might not be able to follow it com-
pletely. But pretty much everybody can 
follow what you’re talking about with stem 
cells because, in a way, it’s much simpler.
But the public perception is slightly 
different; there are a lot of false expectations. 
So, you can say that there’s now a solution to 
nuclear transfer, and that’s true scientifi  cally, 
but it doesn’t really change anything for the 
public yet. iPS cells are a great step forward 
too, in terms of basic science, but it doesn’t 
really bring any stem cell therapies closer to 
the clinic at this point. There’s a crossroads 
between communicating to other scientists 
while, at the same time, being mindful of 
how the public perceives certain ideas.
MAPPING OUT THE FUTURE
When did you ﬁ  rst get interested in 
epigenetics?
It started when we did the 
nuclear transfer experiments 
because the genomes don’t 
always completely repro-
gram. One of my fi  rst thesis 
projects was to set up bisulfi  te 
sequencing—which nobody 
was doing in the laboratory—
to monitor how successful 
reprogramming would reset 
DNA methylation.
There was a nice mo-
ment when I had a chat with Rudolf and 
Eric Lander and we decided to move the 
studies to a genomic scale, and I had sev-
eral meetings with people at the Broad—in 
particular Andreas Gnirke—to discuss how 
to do this. Andi and I spent about two years 
working out the procedures and published 
a small paper in 2005, based on classical 
Sanger sequencing, that showed you could, 
in principle, measure DNA methylation 
genome-wide. We didn’t actually do it 
though, because it was too expensive.
But then we used next-generation 
sequencing technologies to run a lot more 
samples on a genomic scale, and that was 
published last year in Nature as the culmina-
tion of almost fi  ve years of work. Now this 
has moved into the next phase where, to-
gether with Brad Bernstein, I’m directing the 
Epigenome Initiative of the Broad and one of 
the NIH’s Reference Epigenome Mapping 
Centers. The goal is to have complete chro-
matin and DNA methylation maps for every 
cell type in the human body. Right now we 
want to produce a human embryonic stem 
cell epigenome, that’s as comprehensive as 
possible so it can serve as a real reference.
What is your laboratory working on now?
There are a lot of projects that relate to the 
basic mechanisms of how epigenetic mark-
ers are established and maintained during 
normal development. On the reprogramming 
front, we’re trying to understand the epige-
nome of stem cells and how it compares to 
other cell types. What changes when you go 
from A to B? Right now, this is confi  ned 
mostly to iPS cells, but there’s a more general 
interest in how you defi  ne the state of a cell.
In collaboration with groups at MIT 
and Memorial Sloan-Kettering, we’re also 
applying this to cancer, which is one of 
the diseases where epige-
netics play a major role. We 
want to know what changes 
in the epigenetic makeup of 
tumor cells.
What are the next chal-
lenges in the iPS cell ﬁ  eld?
To be therapeutically useful, 
you ultimately need to make 
safe iPS cells, which means 
making them without any vi-
ral integrations. We don’t 
play such a big role in that, but the other 
main question is how can you determine the 
quality of all these cells that you’re gener-
ating? That’s a much bigger challenge in 
human than in mouse, because researchers 
can make mouse chimeras and test for germ-
line contribution. In humans, you have to 
resort to alternative approaches to defi  ne the 
quality of your cells. A lot of our basic work 
on stem cell biology and epigenetics relates 
to fi  guring out a way to quickly screen for 
the best ones. With a good reference map, 
you might identify spots where you really 
need to look for variation that will tell you 
whether your cells are reprogrammed or not.
When we have iPS cells that pose no 
health risk, we’ll still have to fi  gure out how 
to use them. How do you differentiate them 
back into target cell types? How do you 
genetically manipulate them to correct de-
fects? These are challenges that existed be-
fore iPS cells so people will have to go back 
and do the same work that has been going 
on for the last 10 years with ES cells.
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Meissner enjoys the extra beneﬁ  ts of scientiﬁ  c 
meetings: traveling and snowboarding.
“The goal is to 
have complete 
chromatin 
and DNA 
methylation 
maps for every 
cell type in the 
human body.”